

REMARKS/ARGUMENTS

The Claims in the case are 1-5, 12, and 16. Claims 9-11 and 13-14 were cancelled in the preliminary amendment filed June 15, 2006. Claims 6-8, 15 and 17-18 were cancelled in the previous paper filed May 21, 2008. A response to an earlier restriction requirement was filed December 22, 2008.

The Examiner has made a third restriction requirement listing 10 groups. Applicants elect Group IX for examination, drawn to compounds wherein

$a^1-a^2=a^3-a^4$ is $N-CH=CH-CH$ and


Z is NH;

X¹ is NR¹¹;

X² is O or O-C₁₋₂ alkyl;

and Y is C₃₋₉ alkyl or C₃₋₉ alkenyl.

For search purposes, Applicants elect as species, the compound I having the name of 7*H*,19*H*-4,6-ethanediylideneprymido[4,5-*b*][13,1,4,6]benzoxa-triazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-



The structure of this compound is

which is the compound prepared in Example B1 at page 41 of the Specification. The elected compound falls within Group IX. The claims remaining in the application: 1-5, 12, and 16, read on the elected group.

Examination on the merits is respectfully requested.

Respectfully submitted,

/Hesna J. Pfeiffer/

Johnson & Johnson

One Johnson & Johnson Plaza

New Brunswick, NJ 08933-7003

Phone: (732) 524-2830

Dated: June 12, 2009

By:

Hesna J. Pfeiffer, Reg. 22,640